No Data
No Data
Leap and Siro Unite to Unlock Total Sales Transparency With New Integration in SalesPro
Leap Therapeutics Completes Enrollment in Part B of DeFianCe Study
Express News | Leap Therapeutics Announces Completion of Enrollment in Part B of the Defiance Study of Dkn-01 for the Treatment of Colorectal Cancer Patients
Leap LLC Secures Spot on the Inc. 5000 Fastest-Growing Companies List for the Fourth Consecutive Year
Baird Maintains Leap Therapeutics(LPTX.US) With Buy Rating, Maintains Target Price $9
Optimistic Buy Rating on Leap Therapeutics Amid Promising Phase 2 Cancer Trial Outcomes